邁博藥業-B:2023年度報告
Maibo Pharmaceutical-B (02181.HK): net loss of 209 million yuan in 2023
On March 26, Ge Longhui | Maibo Pharmaceutical-B (02181.HK) announced that for the year ended December 31, 2023, the Group's revenue increased 55.9% year-on-year to RMB 87.161 million, mainly due to a sharp increase in drug sales revenue during the reporting period compared to last year. Losses attributable to company owners were approximately RMB 209 million, while losses attributable to company owners during the same period last year were approximately RMB 211 million, with a basic loss of RMB 0.05 per share.
Maibo Pharmaceutical-B (02181) announced 2023 results, operating revenue of about 87.161 million yuan, a year-on-year increase of 55.9%
Maibo Pharmaceutical-B (02181) announced its 2023 results, with revenue of about 87.161 million yuan, a year-on-year increase...
MABPHARM-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Maibo Pharmaceutical-B (02181.HK) will hold a board meeting on March 26 to approve the annual results
Gelonghui March 13 | Maibo Pharmaceutical-B (02181.HK) issued an announcement. The board of directors of the company will hold a board meeting on March 26, 2024 to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended December 31, 2023.
Some Mabpharm Limited (HKG:2181) Shareholders Look For Exit As Shares Take 41% Pounding
The Mabpharm Limited (HKG:2181) share price has fared very poorly over the last month, falling by a substantial 41%. The drop over the last 30 days has capped off a tough year for shareholders, wit
Maibo Pharmaceutical-B [02181] is now reported at HK$0.55, an increase of 12.25%
As of 09:45 Maibo Pharmaceutical-B [02181] reported HK$0.55, up HK$0.06 or 12.25% from yesterday's closing price, with a turnover of HK$0.55, today's highest price of HK$0.55, and the lowest price of HK$0.55. Based on yesterday's closing price, the 10-day average price is HK$0.49 and the 50-day average price is HK$0.47. The current price-earnings ratio is -8.55 times, and the 14-day strength index is 51.35.
The Recent HK$433m Market Cap Decrease Is Likely to Have Disappointed Insiders Invested in Mabpharm Limited (HKG:2181)
Key Insights Significant insider control over Mabpharm implies vested interests in company growth 68% of the business is held by the top 2 shareholders Ownership research, combined with past perf
MABPHARM-B: 2023 Interim Report
Maibo Pharmaceutical-B (02181) released interim results. Losses attributable to shareholders of 99.999 million yuan decreased by 14.4% year-on-year
Maibo Pharmaceutical-B (02181) announced its interim results for the 6 months ended June 30, 2023. The group achieved...
MABPHARM-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
[Hong Kong Stock Connect] Xiansheng Pharmaceutical (02096) and Maibo Pharmaceutical (02181) reach a commercial rights cooperation agreement on rectal cancer drugs
Xiansheng Pharmaceutical (02096) announced that the Group and Maibo Pharmaceutical (02181) have signed a cooperation agreement on CMAB009. According to this, the Group will obtain CMAB009's exclusive commercial rights in mainland China (cooperation area) (including but not limited to sales management, marketing promotion, formulation and adjustment of related strategies, and the right to obtain benefits related to CMAB009). On the basis of complying with the provisions of this agreement, the Group will have the right to provide exclusive promotional services relating to CMAB009 in the cooperative regions. CMAB009 is a recombinant anti-epidermal growth factor receptor (EGFR) chimeric mono
Maibo Pharmaceutical-B (02181.HK) will hold a board meeting on August 25 to approve interim results
Gronway August 14丨Maibo Pharmaceutical-B (02181.HK) announced that the board meeting will be held on August 25, 2023 to consider and approve the interim results of the company and its subsidiaries for the six months ended June 30, 2023.
MABPHARM-B: DATE OF BOARD MEETING
Insiders Were the Key Beneficiaries as Mabpharm Limited's (HKG:2181) Market Cap Rises to HK$3.1b
Key Insights Insiders appear to have a vested interest in Mabpharm's growth, as seen by their sizeable ownership A total of 2 investors have a majority stake in the company with 68% ownership Usin
China Gives New Drug Application Approval to Mabpharm's Anti-Asthma Therapy
China's medical products authority approved Mabpharm's (HKG:2181) new drug application for its CMAB007 injection for immunoglobulin E-mediated asthma, according to a Tuesday filing. The injection, whi
Is Mabpharm (HKG:2181) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Maibo Pharmaceutical-B: 2022 Annual Report
Maibo Pharmaceutical-B: Annual Results Announcement for the Year Ended December 31, 2022
Insiders the Biggest Winners as Mabpharm Limited's (HKG:2181) Market Cap Rises to HK$2.9b
Key Insights Significant insider control over Mabpharm implies vested interests in company growth A total of 2 investors have a majority stake in the company with 68% ownership Past performance o
No Data